Prolia 60 mg/mL
Prolia 60 mg/mL Prolia contains Denosumab, a human monoclonal antibody (IgG2) that targets and binds with high affinity to RANKL (receptor activator of nuclear factor kappa-B ligand). By inhibiting RANKL, it prevents the activation of its receptor RANK on the surface of osteoclasts and their precursors, thereby suppressing osteoclast formation, function, and survival, leading to decreased bone resorption and increased bone mineral density. It is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer, bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer, and glucocorticoid-induced osteoporosis.
| Brand | Prolia |
| Storage Temperature | Store between 2°C to 8°C (Refrigerate in original carton, Do not freeze, Protect from light) |
| Prescription Needed | Yes |
| Composition | Each prefilled syringe contains 60 mg denosumab, 17 mM acetate, 0.01% polysorbate 20, sodium hydroxide to a pH of 5.2, 4.7% sorbitol, Water for Injection, USP. |
| Strength | 60 mg |
| Form | Solution for Injection |
| Pack Size | 1 Prefilled Syringe |
| Packaging | Single-use prefilled syringe |
| Manufacturer | Amgen Inc. |
Prolia 60 mg/mL
Prolia 60 mg/mL Prolia contains Denosumab, a human monoclonal antibody (IgG2) that targets and binds with high affinity to RANKL (receptor activator of nuclear factor kappa-B ligand). By inhibiting RANKL, it prevents the activation of its receptor RANK on the surface of osteoclasts and their precursors, thereby suppressing osteoclast formation, function, and survival, leading to decreased bone resorption and increased bone mineral density. It is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer, bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer, and glucocorticoid-induced osteoporosis.
